“The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the adapted (sub-variant) Covid-19 monovalent vaccine Omicron JN.1“, which may be administered to the “people aged 6 months and over“, according to a joint statement from the two laboratories.
New sub-variants of the virus, all members of the Omicron JN.1 lineage, are currently spreading in several countries, including France, while an immune decline is observed in the population and existing vaccines do not provide any protection. appropriate response.
The European Commission, which is responsible for approving medicines, generally aligns with the EMA’s recommendations within two months.
Since the first wave of Covid-19 in early 2020, the German SME and the American giant have designed a vaccine based on messenger RNA, a molecule allowing the human body to create viral proteins which will trigger an immune response.
Production already launched for the EU, awaiting FDA validation in the United States
This innovative technology has quickly become dominant in anti-Covid vaccination campaigns in Western countries due to its high effectiveness.
Pfizer and BioNTech say they have already started production of the vaccine against the Omicron JN.1 variant in order to be able to supply EU countries by the next autumn-winter season 2024-2025, when demand for vaccination is expected to increase.
https://www.whatsupdoc-lemag.fr/article/il-sest-fait-vacciner-217-fois-du-covid-pour-frauder-son-cas-dhomme-le-plus-vaccine-de
At the same time, the two partners indicate that they have requested a similar marketing authorization from the United States Food and Drug Administration (FDA).
With AFP
